Biohaven (BHVN) Operating Leases (2021 - 2026)
Biohaven (BHVN) posted Operating Leases of $38.4 million for Q1 2026, down 3.99% sequentially from $40.0 million in Q4 2025, and up 24.54% YoY from $30.8 million in Q1 2025.
Biohaven (BHVN) Operating Leases (2021 - 2026) Analysis & Trends
Biohaven has reported Operating Leases for 6 years, with the latest figure at $38.4 million in Q1 2026.
- Quarterly Operating Leases rose 24.54% year-over-year to $38.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.4 million (up 24.54% YoY) and the FY2025 annual result came in at $40.0 million, up 9.22% from the prior year.
- Operating Leases fell to $38.4 million in Q1 2026 per BHVN's latest filing, from $40.0 million in the prior quarter.
- Over five years, Operating Leases peaked at $40.4 million in Q3 2025 and troughed at $25.3 million in Q3 2024.
- A 5-year average of $31.4 million and a median of $29.8 million in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2024: Operating Leases soared 993.35% in 2022, then retreated 10.51% in 2024.
- Over 5 years, Operating Leases stood at $30.6 million in 2022, then slipped by 9.85% to $27.6 million in 2023, then jumped by 32.7% to $36.6 million in 2024, then advanced by 9.22% to $40.0 million in 2025, then declined by 3.99% to $38.4 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $38.4 million, $40.0 million, and $40.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Biohaven | 2.21 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.89 Mn |
| Mar 31, 2026 | 38.36 Mn |
| Dec 31, 2025 | 39.96 Mn |
| Sep 30, 2025 | 40.39 Mn |
| Jun 30, 2025 | 29.80 Mn |
| Mar 31, 2025 | 30.80 Mn |
| Dec 31, 2024 | 36.58 Mn |
| Sep 30, 2024 | 25.31 Mn |
| Jun 30, 2024 | 26.19 Mn |
| Mar 31, 2024 | 27.09 Mn |
| Dec 31, 2023 | 27.57 Mn |
| Sep 30, 2023 | 28.29 Mn |
| Jun 30, 2023 | 29.12 Mn |
| Mar 31, 2023 | 29.76 Mn |
| Dec 31, 2022 | 30.58 Mn |
| Dec 31, 2021 | 2.80 Mn |